However, men with a family history of prostate cancer have often been feared to have a more aggressive form of the disease not otherwise represented by these three factors and therefore are sometimes urged to undergo more aggressive treatment.
Now, Mark Buyyounouski, M.D., M.S., a radiation oncologist at Fox Chase, reports that men with a family history of prostate cancer should expect equally good outcomes following radiotherapy for prostate cancer as patients without a family history. Buyyounouski will be introducing the new data at the 53rd annual meeting of the American Society of Radiation Oncology on Wednesday, October 5th.
PSA, GS, and DRE are well established risk factors for prostate cancer that are used everyday to help make decisions about what treatment option may be best for a patient with the disease. These factors appear in both the American Joint Cancer Commission (AJCC) and National Comprehensive Cancer Network (NCCN) model to stratify risk of recurrence and guide treatment. Yet, in some instances, physicians use a family history of prostate cancer to evaluate the degree of risk associated with the cancer and recommend more aggressive treatment.
In the study, Buyyounouski and his team of collaborators examined 1,711 men who received three-dimensional conformal (3DCRT) or intensity modulated radiotherapy (IMRT) between 1989 and 2007 at Fox Chase Cancer Center in Philadelphia. A positive family history was defined as any prostate cancer in one or more first-degree relatives. Twenty-eight percent of the patients had a positive family history for prostate cancer. The median follow-up from completion of treatment was 71 months.
"What we learned was that whether the men had a history of prostate cancer or not, all had equivalent PSA controls, freedom from metastasis, recurrence-free survival, and overall survival," says Buyyounouski. "Patients should feel comfortable knowing that when they receive radiotherapy having a history of prostate cancer in the family doesn't compromise the results. This is important because patients, especially those with a family history, might assume that radiotherapy might not work as well and opt for surgery when it may not be necessary."
Interestingly, Buyyounouski and his colleagues also learned that men with a family history of prostate cancer were more likely to be younger, have a lower PSA, and non-palpable disease.
"This study shows that patients with a family history are being screened and diagnosed with prostate cancer earlier. Careful screening may have contributed to the good results we observed."
Study co-authors include Hilary Bagshaw, Karen Ruth, Eric M. Horwitz, and David Chen from.
Fox Chase Cancer Center is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's Web site at www.foxchase.org or call 1-888-FOX CHASE or (1-888-369-2427).
Diana Quattrone | EurekAlert!
New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center
Pain: Perception and motor impulses arise in the brain independently of one another
12.12.2018 | Technische Universität München
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.
Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
12.12.2018 | Health and Medicine
12.12.2018 | Physics and Astronomy
12.12.2018 | Health and Medicine